文献速递前列腺癌

体重指数与转移性激素敏感性前列腺癌患者总生存期的相关性:SWOG-1216 患者水平数据分析

Correlation of Body Mass Index with Overall Survival Among Patients with Metastatic Hormone-sensitive Prostate Cancer: Analysis of Patient-level Data from SWOG-1216.
PubMed 文献 · Eur Urol Oncol · 2024-11-08

本研究对 SWOG-1216 试验的患者水平数据进行事后探索性分析,评估基线体重指数(BMI)与转移性激素敏感性前列腺癌(mHSPC)总生存期(OS)的关系。共纳入 1279 例患者,按 BMI 分为体重不足 12 例(0.9%)、正常 252 例(19.7%)、超重 958 例(74.9%)和肥胖 57 例(4.5%)。校正预后变量后,较高的 BMI 与更好的 OS 相关(BMI 类别每增加一级的 HR 为 0.829,95%CI 0.68-0.98;p=0.029)。

要点

  • SWOG-1216 事后探索性分析纳入 1279 例 mHSPC 患者,评估基线 BMI 与 OS 的关系。
  • 体重不足、正常、超重和肥胖组的中位 OS 分别为 2.4、5.5、6.6 和 6.8 年。
  • 校正预后变量后,较高的 BMI 与更好的 OS 相关(HR 0.829,95%CI 0.68-0.98;p=0.029)。

核心结论

  • 在 mHSPC 患者中,校正预后变量后较高的 BMI 与更好的 OS 相关(BMI 类别每增加一级的 HR 为 0.829,95%CI 0.68-0.98;p=0.029)。
  • 这些发现需要在其他 3 期试验中验证。

研究设计与样本

  • SWOG-1216 试验的事后探索性分析,使用患者水平数据。
  • SWOG-1216 为开放标签 3 期试验,将新诊断 mHSPC 患者按 1:1 随机分配至雄激素剥夺治疗(ADT)联合 orteronel(实验组)或 ADT 联合比卡鲁胺(对照组)。
  • 分析共纳入 1279 例患者。

主要发现

  • 体重不足组 12 例(0.9%),正常 BMI 组 252 例(19.7%),超重组 958 例(74.9%),肥胖组 57 例(4.5%)。
  • 年龄、Gleason 评分、疾病负荷范围、内脏转移发生率和治疗分配在各组间相似(p>0.05),而基线前列腺特异性抗原和 Zubrod 体能状态存在差异(p<0.05)。
  • 体重不足、正常、超重和肥胖组的中位 OS 分别为 2.4、5.5、6.6 和 6.8 年。
  • 校正预后变量后,较高的 BMI 与更好的 OS 相关(BMI 类别每增加一级的 HR 为 0.829,95%CI 0.68-0.98;p=0.029)。

局限性

  • 这些发现需要在其他 3 期试验中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although obesity has been associated with better overall survival (OS) among patients with metastatic castration-resistant prostate cancer, its association with OS has not been extensively explored in metastatic hormone-sensitive prostate cancer (mHSPC). We conducted a post hoc exploratory analysis of patient-level data from the SWOG-1216 trial to determine whether baseline body mass index (BMI) is associated with better OS among patients with mHSPC. SWOG-1216 was an open-label, phase 3 trial that randomized patients newly diagnosed with mHSPC 1:1 to either androgen deprivation therapy (ADT) with orteronel (experimental arm) or ADT with bicalutamide (control arm). Of 1279 patients included in the analysis, 12 (0.9%) were underweight, 252 (19.7%) had normal BMI, 958 (74.9%) were overweight, and 57 (4.5%) were obese. Age, Gleason score, extent of disease burden, the incidence of visceral metastases, and treatment allocation were similar among the groups (p > 0.05), while differences in baseline prostate-specific antigen and Zubrod performance status were observed (p < 0.05). Median OS was 2.4, 5.5, 6.6, and 6.8 yr in the underweight, normal, overweight, and obese groups, respectively. After adjusting for prognostic variables, high BMI was associated with better OS (HR for each increment in BMI category: 0.829, 5% CI 0.68-0.98; p = 0.029). These findings need to be validated in other phase 3 trials. PATIENT SUMMARY: We analyzed data from a clinical trial to evaluate the association between body mass index (BMI) and overall survival among patients with metastatic hormone-sensitive prostate cancer. We found that in this group of patients, the risk of death was lower for patients with higher BMI.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Swami U, Jo Y, Narang A, et al. Correlation of Body Mass Index with Overall Survival Among Patients with Metastatic Hormone-sensitive Prostate Cancer: Analysis of Patient-level Data from SWOG-1216. Eur Urol Oncol. 2024. PMID: 39521639. doi:10.1016/j.euo.2024.10.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。